Host–pathogen
ATR inhibitor blocks SARS-CoV-2
Open access · cc by · source: Europe PMC
DDR/ATR inhibitor berzosertib potently blocks SARS-CoV-2 replication in cell culture.
Study at a glance
- Design
- Animal / in-vitro — Medium-throughput SARS-CoV-2 antiviral screen of kinase inhibitors in Vero E6 cells
- N
- ~430 kinase inhibitors screened; cell-assay study without a human sample N
- Population
- Vero E6 cells infected with SARS-CoV-2
- Outcome
- Antiviral activity of kinase inhibitors (notably berzosertib/ATR)
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Berzosertib (ATR inhibitor) showed strong antiviral activity; 100 nM fully blocked replication at 48 hpi in their assay.
Methodology
Built a Vero E6 SARS-CoV-2 assay and screened ~430 kinase inhibitors for antiviral activity with low toxicity.
Limitations
Not a completed human clinical efficacy trial for COVID-19.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
A Vero E6 SARS-CoV-2 assay screened about 430 kinase inhibitors: the ATR inhibitor berzosertib showed strong antiviral activity, and 100 nM fully blocked replication at 48 hours post-infection in that assay. Infection staining or antigen IF is a screening endpoint, not a completed human COVID-19 efficacy trial.
Evidence for the claim as stated.
IF is a screening camera in Vero cells (berzosertib 100 nM, 48 hpi), a tissue census in TB lung (35 patients), a trafficking assay for Smo/Rab5/spike, and a polarity assay in enteroids. 'Positive staining' in a drug screen is not the same claim as PD-1 on human tissue-resident T cells or as K140/K165 moving Rab5 off endosomes.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
IF is a screening camera in Vero cells (berzosertib 100 nM, 48 hpi), a tissue census in TB lung (35 patients), a trafficking assay for Smo/Rab5/spike, and a polarity assay in enteroids. 'Positive staining' in a drug screen is not the same claim as PD-1 on human tissue-resident T cells or as K140/K165 moving Rab5 off endosomes.
- Supports · PD-1 blockade reactivates TB via TNF
- Supports · How does monoubiquitin turn down Rab5?
- Supports · Apical-out enteroids for pathogen access
Related papers in this topic
Same topic cluster — not a recommendation engine.